MariMed Inc. Reports on Security Holder Votes
Ticker: MRMD · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1522767
| Field | Detail |
|---|---|
| Company | Marimed Inc. (MRMD) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: MRMD
TL;DR
MariMed shareholders voted on something important, filing confirms.
AI Summary
MariMed Inc. filed an 8-K on June 6, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or outcomes, but it serves as an official notification of such events.
Why It Matters
This filing indicates that MariMed Inc. has held or is holding a vote of its shareholders, which could pertain to significant corporate decisions or governance matters.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new financial risks or material adverse events.
Key Players & Entities
- MARIMED INC. (company) — Registrant
- June 6, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Norwood, MA (location) — Principal Executive Offices
FAQ
What specific matters were submitted for a vote by MariMed Inc. security holders?
The filing does not specify the exact matters submitted for a vote, only that such matters were presented.
When did the event related to the security holder vote occur or become effective?
The earliest event reported in this filing is dated June 6, 2024.
Is this filing related to a specific corporate action like an acquisition or merger?
The filing indicates 'Submission of Matters to a Vote of Security Holders' and does not explicitly mention an acquisition or merger.
What is the principal executive office address for MariMed Inc.?
The principal executive offices are located at 10 Oceana Way, Norwood, MA 02062.
Does this 8-K filing provide any financial results or guidance?
No, this 8-K filing is specifically for reporting matters submitted to a vote of security holders and does not contain financial results or guidance.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-06-06 17:07:55
Filing Documents
- mrmd-20240606.htm (8-K) — 35KB
- 0001522767-24-000045.txt ( ) — 148KB
- mrmd-20240606.xsd (EX-101.SCH) — 2KB
- mrmd-20240606_lab.xml (EX-101.LAB) — 20KB
- mrmd-20240606_pre.xml (EX-101.PRE) — 11KB
- mrmd-20240606_htm.xml (XML) — 2KB
07. Submission of Matters to Vote of Security Holders
Item 5.07. Submission of Matters to Vote of Security Holders. On June 6, 2024, MariMed Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") to consider and vote on the matters listed below. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 29, 2024. At the Annual Meeting, the Company's stockholders: re-elected the Company's five directors to serve until the Company's next annual meeting of stockholders or until their respective successors have been duly elected and qualified (the "Election of Directors"); and approved, on an advisory basis, the appointment of M&K CPAs PLLC as the Company's independent auditors for the 2024 fiscal year the ("Advisory Approval of Auditors"). The specific votes were as follows: 1. Election of Directors: VOTES NAME FOR WITHHELD BROKER NON-VOTE Jon R. Levine 119,999,444 1,789,093 88,192,628 Edward Gildea 119,626,925 2,161,612 88,192,628 David Allen 120,341,099 1,447,438 88,192,628 Eva Selhub, M.D. 120,565,567 1,222,970 88,192,628 Kathleen Tucker 120,401,629 1,386,908 88,192,628 2. Advisory Approval of Auditors: VOTES FOR AGAINST ABSTAIN/WITHHELD 205,177,744 1,033,085 3,770,336 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MARIMED INC. Dated: June 6, 2024 By: /s/ Jon R. Levine Jon R. Levine President, Chief Executive Officer and Interim Chief Financial Officer